HIV/AIDS Prevention

HIV prevention drug gets U.S. FDA clearance to advance in phase 1 clinical trial

Published in AIDS Vaccine Week, August 30th, 2004

Starpharma Holdings Limited (SPL) announced that VivaGel, its new drug for the prevention of HIV, is advancing to the next stage of dosing in the current phase 1 study.

The U.S. Food and Drug Administration (FDA) has reviewed Starpharma's interim study results and has given clearance to proceed using the highest dosage concentrate planned for this study.

This next stage involves administration of VivaGel containing 3.0% of the active dendrimer ingredient, SPL7013, and placebo gel to a group of healthy women. This is the continuation of the U.S. IND Study No. SPL7013-001, investigating escalating formulation strengths of VivaGel. The study is the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Vaccine Week

Source: AIDS Vaccine Week (2004-08-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry